// App-Quantinova.ai

2224 : Recombinant B-Domain Deleted Porcine Factor VIII (OBI-1) Safety and Efficacy in the Treatment of Acquired Hemophilia A: Interim Results.

Researchers

Presenter

  • Rebecca Kruse-Jarres

Principal Investigators

  • Anne Greist

  • Thrombosis Ctr

  • Amy D. Shapiro

  • Hedy Smith

  • Anja B Drebes

  • Jay N. Lozier

  • Edward D. Gomperts

Medical Centers

  • Department of Hematology, Hopital Maisonneuve Rosemont, Montreal, Canada

  • Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free NHS Trust, London, United Kingdom

Locations

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • FVIII

  • Susoctocog alfa

Outcome

  • N/A

Study Design

  • open label

Phase

  • II/III

Study Id's

  • NCT01178294

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved